Earli
South San Francisco
About Earli
Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $59.9M
- Last round: Series Unknown (Aug 2024)
- Website: earli.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/earli-87047 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.